Unity Biotechnology Company
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
Investors
Technology:
Geroscience
Industry:
Small & Large Molecules
Headquarters:
California, United States
Founded Date:
2009
Employees Number:
51-100
Funding Status:
Series C
Investors Number:
23
Total Funding:
210.6M
Estimated Revenue:
$10M to $50M
Last Funding Date:
Mar 19, 2018
Last Funding Type:
Series C
Register and Claim Ownership